AH-7921; Adverse effects; Fatalities; Fentanyl; MT-45; New psychoactive substances; Psychiatric complications; Somatic complications; Substance use disorder; Synthetic opioids; U-47700
Résumé :
[en] Synthetic opioids (SO) are a major risk for public health across the world. These drugs can be divided into 2 categories, pharmaceutical and non-pharmaceutical fentanyls. A new generation of SO has emerged on the drug market since 2010. North America is currently facing an opioid epidemic of morbi-mortality, caused by over-prescription of opioids, illegally diverted prescribed medicines, the increasing use of heroin, is and the emergence of SO. Furthermore, this opioid crisis is also seen in Europe. SO are new psychoactive substances characterized by different feature such as easy availability on the Internet, low price, purity, legality, and lack of detection in laboratory tests. They have not been approved or are not recommended for human use. Opioid misuse is associated with somatic and psychiatric complications. For many substances, limited pharmacological information is available, increasing the risk of harmful adverse events. Health actors and the general population need to be clearly informed of the potential risks and consequences of the diffusion and use of SO.
Disciplines :
Neurosciences & comportement
Auteur, co-auteur :
Karila, Laurent
Marillier, Maude
Chaumette, Boris
BILLIEUX, Joël ; University of Luxembourg > Faculty of Language and Literature, Humanities, Arts and Education (FLSHASE) > Integrative Research Unit: Social and Individual Development (INSIDE)
Nicolas, Franchitto
Amine, Benyamina
Co-auteurs externes :
yes
Langue du document :
Anglais
Titre :
New synthetic opioids: Part of a new addiction landscape.
Date de publication/diffusion :
2019
Titre du périodique :
Neuroscience and Biobehavioral Reviews
ISSN :
0149-7634
eISSN :
1873-7528
Maison d'édition :
Elsevier, Royaume-Uni
Volume/Tome :
106
Pagination :
133-140
Peer reviewed :
Peer reviewed vérifié par ORBi
Commentaire :
Copyright (c) 2018 Elsevier Ltd. All rights reserved.